T1	p 73 114	acute nonlymphocytic leukemia in adults .
T2	p 419 456	adult acute nonlymphocytic leukemia (
T3	p 628 674	101 eligible cases ( bestatin : 48 , control :
T4	p 959 967	50-65 yr
T5	i 37 55	chemoimmunotherapy
T6	i 61 69	bestatin
T7	i 157 171	INN : Ubenimex
T8	i 337 359	bestatin immunotherapy
T9	i 380 414	remission maintenance chemotherapy
T10	i 552 560	bestatin
T11	i 587 599	po ) daily )
T12	i 608 623	control group .
T13	i 665 674	control :
T14	i 700 708	bestatin
T15	o 731 740	remission
T16	o 803 813	survival .
T17	o 826 851	prolongation of remission
T18	o 1114 1122	survival